Dow Drops as Nvidia Slips After Earnings, Dollar Hits 19-Month High: Stock Market Today
The Dow fell as Nvidia slipped after earnings and the dollar hit a 19-month high, while the S&P 500 held steady after four straight losses.
Follow the latest Humana Inc. (HUM) news and market headlines alongside the live HUM price. Stay informed on what's moving HUM.
The Dow fell as Nvidia slipped after earnings and the dollar hit a 19-month high, while the S&P 500 held steady after four straight losses.
Federal regulators propose sweeping Medicare, Medicaid, and Marketplace anti-fraud reforms projected to save taxpayers nearly $90 billion.
Humana (NYSE:HUM) has outperformed the market over the past 20 years by 2.65% on an annualized basis producing an average annual return of 11.27%. Currently, Humana has a market capitalization of $55.39 billion. Buying
The Centers for Medicare & Medicaid Services (CMS) today issued a proposed rule that could save taxpayers nearly $90 billion over the next 10 years and would strengthen program integrity (PI) oversight and the
The Centers for Medicare & Medicaid Services (CMS) today issued a proposed rule that could save taxpayers nearly $90 billion over the next 10 years and would strengthen program integrity (PI) oversight and the
Program will reward high-performing providers, reduce administrative burden and help patients access care more quicklyHumana Inc. (NYSE:HUM) today announced the launch of its national Gold Card program on December 1, a
Invesco Pharmaceuticals ETF (PJP) delivered 36.1% one-year returns with concentrated pharma exposure, significantly outperforming Simplify Health Care ETF (PINK) at 22.7%. PINK offers lower expenses, broader healthcare diversification, and donates profits to breast cancer research, while PJP provides 20+ years of track record but carries sector concentration risk.
Wells Fargo analyst Stephen Baxter maintains Humana (NYSE:HUM) with a Overweight and raises the price target from $502 to $602.
Humana Inc. has launched a new oncology care model in partnership with Evolent Health and American Oncology Network across eight states. The initiative streamlines prior authorization for qualifying practices, uses EHR analytics and provider scorecards to promote evidence-based cancer treatment, and aims to improve care coordination while reducing specialty care spending. HUM stock has rallied 82.2% over the past year but trades at a premium valuation of 29.08x forward P/E versus the industry average of 15.72x.
Humana (HUM) has been upgraded to Zacks Rank #1 (Strong Buy) due to upward revisions in earnings estimates. The company is expected to earn $9.36 per share for fiscal year 2026, with consensus estimates rising 4.9% over the past three months. The upgrade positions Humana in the top 5% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to HUM, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.